|
1
|
Jemal A, Center MM, DeSantis C and Ward
EM: Global patterns of cancer incidence and mortality rates and
trends. Cancer Epidemiol Biomarkers Prev. 19:1893–1907. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Noori S, Hassan ZM and Salehian O:
Sclareol reduces CD4+CD25+FoxP3+Treg cells in a breast cancer model
in vivo. Iran J Immunol. 10:10–21. 2013.PubMed/NCBI
|
|
3
|
Noori S, Hassan ZM, Mohammadi M, Habibi Z,
Sohrabi N and Bayanolhagh S: Sclareol modulates the Treg
intra-tumoral infiltrated cell and inhibits tumor growth in vivo.
Cellular Immunol. 263:148–153. 2010. View Article : Google Scholar
|
|
4
|
Wang L, He HS, Yu HL, Zeng Y, Han H, He N,
Liu ZG, Wang ZY, Xu SJ and Xiong M: Sclareol, a plant diterpene,
exhibits potent antiproliferative effects via the induction of
apoptosis and mitochondrial membrane potential loss in osteosarcoma
cancer cells. Mol Med Rep. 11:4273–4278. 2015.PubMed/NCBI
|
|
5
|
Sashidhara KV, Rosaiah JN, Kumar A, Bid
HK, Konwar R and Chattopadhyay N: Cell growth inhibitory action of
an unusual labdane diterpene, 13-epi-sclareol in breast and uterine
cancers in vitro. Phytotherapy Res. 21:1105–1108. 2007. View Article : Google Scholar
|
|
6
|
Dimas K, Hatziantoniou S, Tseleni S, Khan
H, Georgopoulos A, Alevizopoulos K, Wyche JH, Pantazis P and
Demetzos C: Sclareol induces apoptosis in human HCT116 colon cancer
cells in vitro and suppression of HCT116 tumor growth in
immunodeficient mice. Apoptosis. 12:685–694. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Simmons GE, Taylor HE and Hildreth JEK:
Caveolin-1 suppresses human immunodeficiency virus-1 replication by
inhibiting acetylation of NF-κB. Virology. 432:110–119. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Garrean S, Gao XP, Brovkovych V, Shimizu
J, Zhao YY, Vogel SM and Malik AB: Caveolin-1 regulates NF-kappaB
activation and lung inflammatory response to sepsis induced by
lipopolysaccharide. J Immunol. 177:4853–4860. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang XM, Kim HP, Song R and Choi AM:
Caveolin-1 confers antiinflammatory effects in murine macrophages
via the MKK3/p38 MAPK pathway. Am J Respir Cell Mol Biol.
34:434–442. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huertas-Martinez J, Rello-Varona S,
Herrero-Martin D, Barrau I, García-Monclús S, Sáinz-Jaspeado M,
Lagares-Tena L, Núñez-Álvarez Y, Mateo-Lozano S, Mora J, et al:
Caveolin-1 is down-regulated in alveolar rhabdomyosarcomas and
negatively regulates tumor growth. Oncotarget. 5:9744–9755. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bender FC, Reymond MA, Bron C and Quest
AF: Caveolin-1 levels are down-regulated in human colon tumors and
ectopic expression of caveolin-1 in colon carcinoma cell lines
reduces cell tumorigenicity. Cancer Res. 60:5870–5878.
2000.PubMed/NCBI
|
|
12
|
Belanger MM, Roussel E and Couet J:
Caveolin-1 is down-regulated in human lung carcinoma and acts as a
candidate tumor suppressor gene. Chest. 125 Supply 5:S1062004.
View Article : Google Scholar
|
|
13
|
Fischer LR, Igoudjil A, Magrané J, Li Y,
Hansen JM, Manfredi G and Glass JD: SOD1 targeted to the
mitochondrial intermembrane space prevents motor neuropathy in the
Sod1 knockout mouse. Brain. 134(Pt 1): 196–209. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Igoudjil A, Magrané J, Fischer LR, Kim HJ,
Hervias I, Dumont M, Cortez C, Glass JD, Starkov AA and Manfredi G:
In vivo pathogenic role of mutant SOD1 localized in the
mitochondrial intermembrane space. J Neurosci. 31:15826–15837.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Somwar R, Erdjument-Bromage H, Larsson E,
Shum D, Lockwood WW, Yang G, Sander C, Ouerfelli O, Tempst PJ,
Djaballah H and Varmus HE: Superoxide dismutase 1 (SOD1) is a
target for a small molecule identified in a screen for inhibitors
of the growth of lung adenocarcinoma cell lines. Proc Natl Acad Sci
USA. 108:pp. 16375–16380. 2011; View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Glasauer A, Sena LA, Diebold LP, Mazar AP
and Chandel NS: Targeting SOD1 reduces experimental non-small-cell
lung cancer. J Clin Invest. 124:117–128. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kirchner P, Bug M and Meyer H:
Ubiquitination of the N-terminal region of caveolin-1 regulates
endosomal sorting by the VCP/p97 AAA-ATPase. J Biol Chem.
288:7363–7372. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hayer A, Stoeber M, Ritz D, Engel S, Meyer
HH and Helenius A: Caveolin-1 is ubiquitinated and targeted to
intralumenal vesicles in endolysosomes for degradation. J Cell
Biol. 191:615–629. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen SF, Wu CH, Lee YM, Tam K, Tsai YC,
Liou JY and Shyue SK: Caveolin-1 interacts with Derlin-1 and
promotes ubiquitination and degradation of cyclooxygenase-2 via
collaboration with p97 complex. J Biol Chem. 288:33462–33469. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen SF, Liou JY, Huang TY, Lin YS, Yeh
AL, Tam K, Tsai TH, Wu KK and Shyue SK: Caveolin-1 facilitates
cyclooxygenase-2 protein degradation. J Cell Biochem. 109:356–362.
2010.PubMed/NCBI
|
|
21
|
Feldman R and Martinez JD: Growth
suppression by ursodeoxycholic acid involves caveolin-1 enhanced
degradation of EGFR. Biochim Biophys Acta. 1793:1387–1394. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Qi L, Zhang XD, Wu JC, Lin F, Wang J,
DiFiglia M and Qin ZH: The role of chaperone-mediated autophagy in
huntingtin degradation. PloS One. 7:e468342012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cuervo AM, Dice JF and Knecht E: A
population of rat liver lysosomes responsible for the selective
uptake and degradation of cytosolic proteins. J Biol Chem.
272:5606–5615. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liang X, Wei SQ, Lee S, Fung JK, Zhang M,
Tanaka A, Choi AM and Jin Y: p62 sequestosome 1/light chain 3b
complex confers cytoprotection on lung epithelial cells after
hyperoxia. Am J Respir Cell Mol Biol. 48:489–496. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gómez-Sánchez R, Yakhine-Diop SM,
Rodríguez-Arribas M, Bravo-San Pedro JM, Martínez-Chacón G,
Uribe-Carretero E, de Castro DC Pinheiro, Pizarro-Estrella E,
Fuentes JM and González-Polo RA: mRNA and protein dataset of
autophagy markers (LC3 and p62) in several cell lines. Data Brief.
7:641–647. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Trimmer C, Bonuccelli G, Katiyar S, Sotgia
F, Pestell RG, Lisanti MP and Capozza F: Cav1 suppresses tumor
growth and metastasis in a murine model of cutaneous SCC through
modulation of MAPK/AP-1 activation. Am J Pathol. 182:992–1004.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Aarhus M, Bruland O, Saetran HA, Mork SJ,
Lund-Johansen M and Knappskog PM: Global gene expression profiling
and tissue microarray reveal novel candidate genes and
down-regulation of the tumor suppressor gene CAV1 in sporadic
vestibular schwannomas. Neurosurgery. 67:998–1019. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shi Y, Tan SH, Ng S, Zhou J, Yang ND, Koo
GB, McMahon KA, Parton RG, Hill MM, Del Pozo MA, et al: Critical
role of CAV1/caveolin-1 in cell stress responses in human breast
cancer cells via modulation of lysosomal function and autophagy.
Autophagy. 11:769–784. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Podar K, Shringarpure R, Tai YT, Simoncini
M, Sattler M, Ishitsuka K, Richardson PG, Hideshima T, Chauhan D
and Anderson KC: Caveolin-1 is required for vascular endothelial
growth factor-triggered multiple myeloma cell migration and is
targeted by bortezomib. Cancer Res. 64:7500–7506. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mao M, Sudhahar V and Fukai T: P54:
Nitroglycerin-induced loss of caveolin-1 results in eNOS
dysfunction, peroxynitrite production and nitrate tolerance. Nitric
Oxide 31, Supplement. 1:S362013. View Article : Google Scholar
|
|
31
|
Salem K, McCormick ML, Wendlandt E, Zhan F
and Goel A: Copper-zinc superoxide dismutase-mediated redox
regulation of bortezomib resistance in multiple myeloma. Redox
Biol. 4:23–33. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen D, Frezza M, Schmitt S, Kanwar J and
Dou QP: Bortezomib as the first proteasome inhibitor anticancer
drug: Current status and future perspectives. Curr Cancer Drug
Targets. 11:239–253. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kao C, Chao A, Tsai CL, Chuang WC, Huang
WP, Chen GC, Lin CY, Wang TH, Wang HS and Lai CH: Bortezomib
enhances cancer cell death by blocking the autophagic flux through
stimulating ERK phosphorylation. Cell Death Dis. 5:e15102014.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kretowski R, Stypulkowska A and
Cechowska-Pasko M: Efficient apoptosis and necrosis induction by
proteasome inhibitor: Bortezomib in the DLD-1 human colon cancer
cell line. Mol Cell Biochem. 398:165–173. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Miyamoto Y, Nakagawa S, Wada-Hiraike O,
Seiki T, Tanikawa M, Hiraike H, Sone K, Nagasaka K, Oda K, Kawana
K, et al: Sequential effects of the proteasome inhibitor bortezomib
and chemotherapeutic agents in uterine cervical cancer cell lines.
Oncol Rep. 29:51–57. 2013.PubMed/NCBI
|
|
36
|
Ando M, Hoyos V, Yagyu S, Tao W, Ramos CA,
Dotti G, Brenner MK and Bouchier-Hayes L: Bortezomib sensitizes
non-small cell lung cancer to mesenchymal stromal cell-delivered
inducible caspase-9-mediated cytotoxicity. Cancer Gene Ther.
21:472–482. 2014. View Article : Google Scholar : PubMed/NCBI
|
